Atorvastatin Reduces Plasma Inflammatory and Oxidant Biomarkers in Patients With Risk of Atherosclerotic Cardiovascular Disease

Autor: Fadia Mayyas, Rasheed K. Ibdah, Duha Baydoun, Khalid S. Ibrahim
Rok vydání: 2018
Předmět:
Adult
Male
0301 basic medicine
medicine.medical_specialty
Atorvastatin
Inflammation
030204 cardiovascular system & hematology
medicine.disease_cause
Gastroenterology
Coronary artery disease
Superoxide dismutase
03 medical and health sciences
0302 clinical medicine
Risk Factors
Internal medicine
medicine
Humans
Pharmacology (medical)
Prospective Studies
Aged
Peroxidase
Pharmacology
Dose-Response Relationship
Drug
Endothelin-1
biology
Superoxide Dismutase
business.industry
C-reactive protein
Middle Aged
Atherosclerosis
Oxidants
medicine.disease
Lipids
Endothelin 1
Oxidative Stress
C-Reactive Protein
030104 developmental biology
Myeloperoxidase
biology.protein
Female
Hydroxymethylglutaryl-CoA Reductase Inhibitors
medicine.symptom
Cardiology and Cardiovascular Medicine
business
Oxidative stress
medicine.drug
Zdroj: Journal of Cardiovascular Pharmacology and Therapeutics. 23:216-225
ISSN: 1940-4034
1074-2484
DOI: 10.1177/1074248417753677
Popis: Oxidative stress and inflammation are associated with endothelial injury and coronary artery disease. Inflammatory factors that promote oxidative damage include endothelin-1 (ET-1), myeloperoxidase (MPO), and C-reactive protein (CRP). Current guidelines recommend the use of statins in patients with risk of atherosclerotic cardiovascular disease (ASCVD).To assess the impact of atorvastatin on plasma inflammatory and oxidant biomarkers in patients with moderate to very high risk of ASCVD.Two hundred ten patients presented to the cardiology clinic were included and stratified into low, moderate, high, and very high risk of ASCVD. Moderate- (20 mg/d) to high-intensity (40 mg/d) atorvastatin was prescribed. Plasma levels of lipids, ET-1, CRP, MPO, total nitrite, lipid peroxides (thiobarbituric acid reactive substances [TBARS]), and superoxide dismutase (SOD) activities were measured at baseline and 12 weeks after treatment.Relative to low-risk patients, baseline plasma inflammatory markers of CRP, MPO, ET-1, and nitrite were higher in patients with very high risk of ASCVD, whereas plasma SOD was lower (all P.05). Use of high and moderate atorvastatin therapy significantly reduced low-density lipoprotein and total cholesterol levels, as well as plasma levels of CRP, MPO, nitrite, and TBARS, and increased plasma SOD activity in patients with moderate to very high risk of ASCVD, independent of lipid-lowering effects.Key markers of oxidative stress/inflammation such as CRP, ET-1, total nitrite, and MPO are associated with an increased risk of ASCVD. Moderate- and high-intensity atorvastatin use reduces plasma oxidative stress and inflammation regardless of ASCVD risk and independent of its lipid-lowering effect.
Databáze: OpenAIRE
Externí odkaz: